Biogen Inc. (BIIB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Biogen CEO Christopher Viehbacher, speaking at the Morgan Stanley Global Healthcare Conference on September 8, 2025, detailed the company's 2.5-year "reinvention" amidst declining MS portfolio sales and slower-than-anticipated growth from LEQEMBI. He highlighted a strategic move to cease all promotion for the MS portfolio, which surprisingly did not affect its sales trajectory, indicating successful cost management while navigating core product challenges.

Analysis

Biogen (BIIB) is navigating a significant strategic pivot driven by fundamental business challenges, as articulated by CEO Christopher Viehbacher. The company faces dual pressures from the confirmed, ongoing decline of its legacy Multiple Sclerosis (MS) portfolio and a slower-than-anticipated commercial ramp-up for its Alzheimer's drug, LEQEMBI, which was expected to be the next major growth engine. This situation, described by the CEO as a 2.5-year "reinvention journey," underscores the instability inherent in a business model reliant on patent lifecycles. A key strategic decision highlighted was the complete withdrawal of promotional support for the MS franchise. This move proved to be a notable success from a cost-management perspective, as it did not negatively alter the portfolio's sales trajectory, indicating the revenue stream is now highly mature and inelastic to marketing spend, thereby freeing up significant capital.

Key Decisions for Investors

• Investors should moderate near-term growth expectations for Biogen, as management has confirmed that the transition from its declining MS portfolio to LEQEMBI is proving slower and more challenging than anticipated.
• The successful cost-cutting on the MS portfolio is a positive signal of operational discipline; it is now critical to monitor how this freed-up capital is reallocated to accelerate LEQEMBI's commercialization or advance other pipeline assets.
• Given the top-line pressures, a cautious stance is warranted until there is tangible evidence of an inflection point in LEQEMBI's sales trajectory, which remains the single most important catalyst for the company's outlook.